证券代码：600538 证券简称：国发股份 公告编号：临 2026-008 重要内容提示 ●公司大股东朱蓉娟持有的公司 1,784 万股无限售流通股股票（占公司总股 本的比例为 3.40%）将于 2026 年 4 月 22 日 10 时至 2026 年 4 月 23 日 10 时止 （延时的除外）被广西壮族自治区南宁市青秀区人民法院司法拍卖。 ●公司目前生产经营一切正常，本次司法拍卖事项不会对公司日常生产经营 产生重大影响。公司将持续努力做好各项经营管理工作，以保障公司稳健经营。 ●目前拍卖事项尚在公示阶段，后续可能涉及竞拍、缴款、股权变更过户等 环节，拍卖结果存在一定的不确定性。公司将根据最终结果，依法履行相应的信 息披露义务。 ●若本次拍卖的 1,784 万股股票成功被拍卖并完成司法过户，公司的控股股 东及实际控制人可能将发生变更。 北海国发川山生物股份有限公司（以下简称"公司"）大股东朱蓉娟及其一致 行动人彭韬等因与广西美强投资有限公司借款合同纠纷案件，导致朱蓉娟持有的 公司 1,784 万股股票将被南宁市青秀区人民法院司法拍卖，现将司法拍卖的具体 情况公告如下： 一、司法拍卖的原因 1、股份质押情况 ...

北京香雅提供 PET/MR、3.0 核磁共振、64 排 128 层 CT、DR、钼靶等影像 诊断设备及远程会诊、诊断中心会诊软件系统以及提供技术与支持服务等作为 投入，宿迁康复体检公司以提供运营场地机房、诊断办公用房、水电设施等作 为投入，双方合作建立医学影像中心，开展医学影像诊疗服务在合作期内，宿 迁康复体检公司每年按影像中心营业收入 10%-22%的比例获取收益。影像中心 每年的营业收入扣除影像中心的成本费用以及宿迁康复体检公司每年获取的收 益后，为北京香雅每年应获得的收益。若影像中心的收入不能覆盖成本费用时， 不足部分由北京香雅承担。 上述事项公司于 2018 年 5 月 4 日、2018 年 5 月 5 日在《上海证券报》《证 券 时 报 》《 证 券 日 报 》《 中 国 证 券 报 》 和 上 海 证 券 交 易 所 网 站 1 北海国发川山生物股份有限公司 关于北京香雅终止宿迁影像中心合作协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北海国发川山生物股份有限公司(以下简称"公司")于 2026 年 ...

Group 1 - The core viewpoint of the news is that BASF, the world's largest chemical giant, has announced a price increase of 30% or more for all household care, industrial, and institutional cleaning products in Europe starting from March 18, primarily due to significant fluctuations in key raw material prices, rising domestic and cross-continental logistics costs, and soaring packaging and energy costs [1] - BASF will also increase its formic acid sales price in Europe by €250 per ton and the price of neopentyl glycol by €350 per ton, effective immediately or as allowed by existing contracts [1] Group 2 - In the A-share market, several chemical stocks have seen price increases, with Xinghua Co. hitting the daily limit, Guofa Co. rising over 3%, and others like Xin'ao Co., Guanghui Energy, Donghua Energy, Dawi Technology, and Shengli Co. increasing by over 2% [1] - The market capitalization and year-to-date performance of notable companies include: - Xinghua Co. with a market cap of ¥6.739 billion and a year-to-date increase of 48.73% [2] - Guofa Co. with a market cap of ¥3.313 billion and a year-to-date increase of 3.27% [2] - Xin'ao Co. with a market cap of ¥70.2 billion and a year-to-date increase of 9.20% [2] - Guanghui Energy with a market cap of ¥44.7 billion and a year-to-date increase of 42.07% [2] - Donghua Energy with a market cap of ¥14.7 billion and a year-to-date increase of 15.06% [2] - Dawi Technology with a market cap of ¥17.3 billion and a year-to-date increase of 62.43% [2] - Shengli Co. with a market cap of ¥4.471 billion and a year-to-date increase of 1.39% [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北海国发川山生物股份有限公司（以下简称"公司"）全资子公司广州高盛 生物科技有限公司（以下简称"高盛生物"）近日收到广东省科学技术厅、广东 省财政厅、国家税务总局广东省税务局联合下发的《高新技术企业证书》（证书 编号：GR202544010869），发证日期：2025 年 12 月 19 日，有效期三年。 本次系高盛生物原高新技术企业证书有效期满后进行的重新认定，根据《中 华人民共和国企业所得税法》及《高新技术企业认定管理办法》等相关规定，高 盛生物自通过高新技术企业认定当年起连续三年可享受国家关于高新技术企业 的税收优惠政策，即按 15%税率缴纳企业所得税。 高盛生物 2025 年已按照 15%的企业所得税税率进行纳税申报及预缴，因此 本次通过高新技术企业认定所享受税收优惠政策不影响公司 2025 年度的相关财 务数据。 证券代码：600538 证券简称：国发股份 公告编号：临 2026-006 北海国发川山生物股份有限公司 关于全资子公司高盛生物获得高新技术企业证书的公告 特 ...

Company Dynamics - Beihai Guofa Chuan Mountain Biological Co., Ltd. (stock code: 600538.SH) has attracted attention from the Shanghai Stock Exchange due to significant goodwill impairment provisions for its judicial appraisal technology subsidiary over the past three years [1] - The company expects to achieve approximately 330 million yuan in revenue for the fiscal year 2025, with a net loss attributable to shareholders of about 85 million yuan, and a net loss of approximately 85.5 million yuan after excluding non-recurring gains and losses [1] Performance Pressure - The performance pressure is directly related to a past acquisition; in 2020, Guofa acquired 99.9779% of Guangzhou Gaosheng Biotechnology Co., Ltd. for 355.6932 million yuan, entering the molecular diagnostics and judicial appraisal service sector [2] - Since 2023, Gaosheng's performance has consistently fallen short of expectations, leading to three consecutive years of goodwill impairment provisions, with 55 million yuan and 60 million yuan recorded for 2023 and 2024 respectively, and an expected additional 65 million yuan for 2025 [2] Market Environment - From 2023 onwards, tightening fiscal spending at various levels has significantly reduced the budget of the core customer, the public security system, leading to a decline in demand for testing equipment and services [3] - The amount won in bids dropped from 110.2131 million yuan in 2022 to 68.1250 million yuan in 2023, a decrease of 38.19%, resulting in a substantial decline in revenue and profit [3] - Actual revenue from 2023 to 2025 is projected to be only 42.25% to 50.35% of the forecasted values, with net profit realization rates between -2.39% and 20.66% [3] Goodwill Impairment Risk - Guofa has issued a clear warning regarding the risk of goodwill impairment, emphasizing that the realization of goodwill from the acquisition of Gaosheng is highly dependent on its future profitability [4] - Factors such as technological iteration, intensified competition, policy adjustments, or subpar market promotion could trigger immediate goodwill impairment [4] - The company highlighted that even minor declines in revenue and gross margin could lead to disproportionately large impairment losses, significantly amplifying overall performance volatility and potentially resulting in a shift from profit to loss [4]

Core Viewpoint - Guofang Co., Ltd. (600538.SH) has reported a continuous loss for three consecutive years, raising significant regulatory concerns regarding its financial performance and future outlook [1][2][3]. Financial Performance - For 2025, Guofang expects to achieve approximately 330 million yuan in revenue, with a net loss attributable to shareholders of around 85 million yuan, and a net loss after excluding non-recurring items of about 85.5 million yuan, reflecting a reduction in losses compared to the previous year [1][3]. - The company has experienced revenue declines of 3.2% year-on-year, with a gross margin of 22.6%, down 3.03 percentage points from the previous year [1][3]. - Historical performance shows fluctuations, with revenues of 460 million yuan, 369 million yuan, and 340 million yuan from 2022 to 2024, alongside net profits of 34.84 million yuan, -82.31 million yuan, and -93.85 million yuan respectively [2][3]. Business Segments - The main business segments include pharmaceutical manufacturing, pharmaceutical distribution, and judicial IVD, generating revenues of 191 million yuan, 27.14 million yuan, and 107 million yuan respectively, with year-on-year changes of 4.43%, -23.44%, and -10% [4]. - The gross margins for these segments are 13.7%, 35.56%, and 36.48%, showing declines in each segment [4]. Impairment of Goodwill - A significant factor affecting Guofang's performance is the impairment of goodwill related to its acquisition of Guangzhou Gaosheng Biotechnology Co., Ltd., which has led to a cumulative impairment provision of 178 million yuan from 2023 to 2025 [5][7]. - The company acquired Gaosheng for 356 million yuan in 2021, which has not met performance expectations, resulting in substantial impairments in 2023 and 2024 [5][6]. - Guofang plans to recognize an additional impairment provision of approximately 62.45 million yuan for 2025, indicating ongoing challenges in achieving projected revenue and profit levels [6][7]. Market Conditions - Increased market competition and a decline in government funding have adversely affected Gaosheng's revenue and profit margins, contributing to the overall financial difficulties faced by Guofang [6][7]. - The company has noted a decrease in orders for its judicial IVD business, which is expected to impact future revenue generation [6].

Core Viewpoint - The company, Guofa Co., Ltd. (国发股份), is facing significant financial challenges due to the underperformance of its acquired subsidiary, Gaoshen Biotechnology, leading to substantial goodwill impairment over three consecutive years [1][2]. Financial Performance - For the fiscal year 2025, Guofa Co. anticipates a revenue of approximately 330 million yuan and a net loss attributable to shareholders of around 85 million yuan, with a non-recurring net loss of about 85.5 million yuan [1]. - The company has reported goodwill impairment provisions of 55 million yuan and 60 million yuan for the years 2023 and 2024, respectively, with an expected provision of about 65 million yuan for 2025 [2]. Acquisition and Goodwill Impairment - Guofa Co. acquired a 99.9779% stake in Gaoshen Biotechnology for approximately 355.69 million yuan in 2020, entering the molecular diagnostics and forensic identification business [1]. - The actual performance of Gaoshen Biotechnology from 2023 to 2025 has significantly deviated from initial profit forecasts, with revenue realization rates between 42.25% and 50.35% [2][3]. Market Conditions and Challenges - The decline in Gaoshen's performance is attributed to reduced customer demand, budget cuts from public security clients, and a decrease in successful bids for projects [3][4]. - In 2023, Gaoshen's bid amounts dropped from 110.21 million yuan in 2022 to 68.13 million yuan, a decrease of 38.19% [4]. Industry Trends - The overall industry is experiencing a downward trend in revenue, with comparable companies showing median revenue declines of 24.23%, 9.74%, and 17.44% for the years 2023 to 2025 [4]. - Guofa Co. acknowledges that the future value of goodwill is highly dependent on Gaoshen's ability to meet expected revenue and profit growth, which is threatened by market competition and other external factors [5].

Core Viewpoint - Guofang Co., Ltd. (600538.SH) responded to the Shanghai Stock Exchange's inquiry regarding its 2025 performance forecast, addressing key issues such as revenue compliance, the reasonableness of pharmaceutical distribution growth, and goodwill impairment [1][3]. Revenue Compliance - The company confirmed that its revenue deductions comply with regulatory requirements, ensuring no unaccounted deductions exist [3]. - The main business segments include pharmaceutical distribution, pharmaceutical manufacturing, judicial IVD, and other businesses, with a slight overall revenue decline expected in 2025 [3]. Pharmaceutical Distribution Growth - Pharmaceutical distribution is the largest business segment, expected to account for 57.87% of total revenue in 2025, with a year-on-year increase of 4.43% driven by increased market share in centralized procurement and rising demand for narcotic drugs [3]. - Centralized procurement revenue is projected to grow by 56%, while narcotic drug revenue is expected to increase by 16%, with a stable customer base primarily consisting of long-term cooperative hospitals [3]. Pharmaceutical Manufacturing and Judicial IVD - The pharmaceutical manufacturing segment is expected to account for 8.24% of total revenue, with a year-on-year decline of 23.44% due to maintenance-related production reductions and adjustments in product structure [4]. - The judicial IVD segment is projected to account for 32.42% of total revenue, with a year-on-year decline of 10% attributed to intensified industry competition, reduced orders, and increased bidding difficulties [4]. Other Business Segment - Other businesses are expected to account for 1.47% of total revenue, with a year-on-year growth of 32.74%, primarily due to a low base and increased consulting service revenue [5]. Goodwill Impairment - The company plans to recognize approximately 62 million yuan in goodwill impairment for its wholly-owned subsidiary, Guangzhou Gaosheng Bio, in 2025, following significant impairments in 2023 and 2024 [1][6]. - The performance decline of Gaosheng Bio is attributed to common industry challenges, including tightened fiscal budgets in the public security system and prolonged payment cycles, with overall industry performance expected to decline from 2023 to 2025 [6]. Future Outlook - The company anticipates that comparable listed companies will show positive revenue growth from 2026 to 2027, with an average growth rate of 12.86% expected for 2027, driven by economic recovery and improved demand for related products and services [6].

Core Viewpoint - Guofang Co., Ltd. (600538) has provided a detailed response to the Shanghai Stock Exchange regarding its 2025 performance forecast, indicating an expected revenue of approximately 330 million yuan and a net loss attributable to shareholders of about 85 million yuan, reflecting a 10% reduction in losses compared to 2024 [1][2]. Revenue Composition - The company anticipates a total revenue of approximately 330 million yuan for 2025, with a net loss of 85 million yuan attributable to shareholders [1][2]. - The revenue forecast includes a significant decline in revenue from its wholly-owned subsidiary, Guangzhou Gaosheng Biotechnology Co., Ltd., which is expected to see a 10% decrease in revenue and a 3% drop in gross margin due to intensified market competition [1][2]. Business Segment Performance - The company operates in several segments: pharmaceutical distribution, pharmaceutical manufacturing, judicial IVD, and other businesses, with overall revenue expected to decline slightly in 2025 [4]. - Pharmaceutical distribution is projected to generate 190.72 million yuan, accounting for 57.87% of total revenue, with a slight increase of 4.43% year-on-year [5]. - Pharmaceutical manufacturing is expected to see a significant decline of 23.44% in revenue, primarily due to production line maintenance and adjustments in sales policies [6]. - Judicial IVD is forecasted to decrease by 10% in revenue, attributed to reduced orders and increased competition [6]. - Other businesses are expected to grow by 32.74%, mainly due to low base effects and additional consulting service income [6]. Customer Structure and Market Dynamics - The pharmaceutical distribution segment's growth is largely driven by long-term relationships with hospitals, with major clients remaining stable [5][6]. - The company has responded to inquiries regarding revenue deductions, confirming that all relevant income has been thoroughly reviewed and complies with regulations [3]. - The company’s revenue growth in the pharmaceutical distribution segment is expected to exceed that of industry peers, with a projected growth rate of over 6% compared to 2024 [6][7]. Goodwill Impairment - The company plans to recognize a goodwill impairment of approximately 62 million yuan for 2025, following previous impairments in 2023 and 2024 [2][8]. - The decline in performance is attributed to broader industry challenges, including budget cuts from public sector clients and increased competition [8].

Core Viewpoint - Guofang Co., Ltd. (600538) has responded to the Shanghai Stock Exchange regarding its 2025 performance forecast, addressing concerns about compliance, growth in circulation business, and continuous goodwill impairment [1] Revenue and Business Performance - The company expects a revenue of approximately 330 million yuan for 2025, with a main business revenue of 327 million yuan after deducting unrelated income of 2.4808 million yuan [3] - The pharmaceutical circulation business is projected to account for nearly 58% of total revenue, showing a year-on-year growth of 4.43%, while the judicial IVD and pharmaceutical manufacturing businesses are expected to decline by 10% and 23.44%, respectively [3][4] Business Segment Analysis - The judicial IVD business is anticipated to generate 107 million yuan in revenue for 2025, a decrease of 10% due to reduced executable orders and intensified market competition, with the backlog of orders at 47.15 million yuan, down 7.22 million yuan from the previous year [4][5] - The pharmaceutical manufacturing segment is expected to achieve revenue of 27.1421 million yuan, down 23.44%, with a decrease in gross margin by 14.12 percentage points, attributed to maintenance of production lines and adjustments in sales policies [5] - The pharmaceutical circulation business is the only growth area, projected to reach 191 million yuan in revenue, a 4.43% increase driven by collective procurement and revenue from narcotic drugs [5] Goodwill Impairment - Guofang Co., Ltd. plans to recognize over 62 million yuan in goodwill impairment for its wholly-owned subsidiary, Guangzhou Gaosheng Biotechnology Co., Ltd., marking the third consecutive year of significant impairment [5] - The adjusted net profit realization rate for Gaosheng Biotechnology was only 26.19% in 2023 and further declined to 23.40% in 2024, with a projected realization rate of just 1.17% for 2025 [6] - The decline in performance is attributed to significant budget cuts from clients and a decrease in successful bids, aligning with industry trends where comparable companies also show a decline in performance from 2023 to 2025 [7]